AMS Earnings

AMS reported its FY2025Q3 earnings on 2025-11-13, showcasing a revenue of 7.17M against an estimate of 7.52M, resulting in a -4.64% surprise. The EPS was 0, surpassing the expected 0 by 0%. The stock experienced a 7.69% price change on the earnings day and a 1.92% change over the next five days, reflecting market reactions to the results.

Following AMS's FY2025Q3 earnings announcement on 2025-11-13, the stock price moved by 7.69% on the day of the release. Over the subsequent five days, it saw a 1.92% change. Historically, AMS's stock price tends to shift by an average of -1.82% in the 10 days leading up to earnings and -3.15% in the 10 days following, providing insight into potential market.

For 2025/Q3, analysts estimate AMS's annual revenue to reach 7.52M, while the EPS is projected at -0.07. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between AMS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AMS's stock price typically moves by -1.82% in the 10 days before its earnings and -3.15% in the 10 days after. For the upcoming 2025/Q3 earnings, analysts expect an EPS of -0.07 and revenue of 7.52M.

The earnings call reveals a mixed performance with declining leasing revenue and gross margins, alongside a net loss. Despite some growth in direct patient care services, the inability to provide guidance, especially on profitability, and the lack of a stock buyback program are concerning. The Q&A section highlights management's reluctance to offer forward-looking statements, contributing to uncertainty. Although there is strategic expansion, the financial health indicators suggest a negative sentiment, likely resulting in a stock price decrease of 2% to 8% over the next two weeks.